Senseonics Earnings Call: Growth and Strategic Moves

Senseonics Holdings Inc. ((SENS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Senseonics Holdings Inc. Earnings Call Highlights Strong Growth and Strategic Collaborations

The recent earnings call of Senseonics Holdings Inc. conveyed a robust positive sentiment, underscored by notable revenue growth, strategic partnerships, and successful integration efforts. Despite a temporary halt in the Mercy Health Systems project, the company remains optimistic about its trajectory, with plans for European expansion and improved financial metrics.

Revenue Growth

Senseonics reported a significant 24% increase in net revenue, reaching $6.3 million in Q1 2025, up from $5 million in the same period last year. This growth reflects the company’s successful market strategies and expanding customer base.

Eversense 365 and twiist Integration

The company announced the integration of its Eversense 365 system with the twiist Automated Insulin Delivery System. This collaboration enables real-time glucose readings and insulin delivery adjustments, enhancing the product’s appeal and functionality.

Collaboration with SweetSpot

A new partnership with SweetSpot was highlighted, aiming to provide virtual continuous glucose monitoring (CGM). This initiative is expected to improve patient care and health outcomes across networks, showcasing Senseonics’ commitment to innovation.

Medicare Reimbursement Update

The 2025 physician fee schedule now includes full-year payments for Eversense, effective retroactively from January 1. This update is a significant step in improving the financial accessibility of the Eversense system.

European Launch Plans

Senseonics has filed a CE Mark application, with plans to launch Eversense 365 in Europe in the latter half of 2025. This expansion is a key component of the company’s growth strategy.

Improved Financial Performance

The company reported a gross profit increase to $1.5 million in Q1 2025, up from $0.3 million in the previous year, with gross margins improving to approximately 18%. This improvement reflects the company’s operational efficiencies and product demand.

Mercy Health Systems Initiative Paused

A restructuring at Mercy Health Systems has temporarily paused the initiative to advance Eversense, impacting expected outcomes later in the year. However, Senseonics remains focused on its strategic objectives.

Net Loss

Senseonics reported a net loss of $14.3 million, or $0.02 per share, in Q1 2025, an improvement from a net loss of $18.9 million, or $0.03 per share, in the same period last year. This reduction in net loss indicates progress towards financial stability.

Forward-Looking Guidance

The company reaffirmed its revenue guidance for 2025, projecting total net revenue between $34 million and $38 million. This follows a strong Q1 performance, with significant contributions from U.S. and international markets. The company is also preparing for a European launch and transitioning U.S. reimbursement to a 365-day model, with many payers already on board.

In conclusion, Senseonics Holdings Inc.’s earnings call highlighted a positive outlook, driven by strategic collaborations, revenue growth, and improved financial performance. The company’s forward-looking guidance and expansion plans further underscore its commitment to innovation and market leadership.